Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma.

Ciarapica R, Russo G, Verginelli F, Raimondi L, Donfrancesco A, Rota R, Giordano A.

Cell Cycle. 2009 Jan 1;8(1):172-5. Epub 2009 Jan 30. No abstract available.


High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.

Jansen MP, Reijm EA, Sieuwerts AM, Ruigrok-Ritstier K, Look MP, Rodríguez-González FG, Heine AA, Martens JW, Sleijfer S, Foekens JA, Berns EM.

Breast Cancer Res Treat. 2012 Jun;133(3):937-47. doi: 10.1007/s10549-011-1877-4. Epub 2011 Nov 18.


MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells.

Dang X, Ma A, Yang L, Hu H, Zhu B, Shang D, Chen T, Luo Y.

Cancer Genet. 2012 Mar;205(3):113-23. doi: 10.1016/j.cancergen.2012.01.002.


Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98.

Alajez NM, Shi W, Hui AB, Bruce J, Lenarduzzi M, Ito E, Yue S, O'Sullivan B, Liu FF.

Cell Death Dis. 2010 Oct 21;1:e85. doi: 10.1038/cddis.2010.64.


Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms.

Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM.

Oncotarget. 2011 Sep;2(9):669-83.


MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta.

Cao P, Deng Z, Wan M, Huang W, Cramer SD, Xu J, Lei M, Sui G.

Mol Cancer. 2010 May 17;9:108. doi: 10.1186/1476-4598-9-108.


Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2.

Esposito F, Tornincasa M, Pallante P, Federico A, Borbone E, Pierantoni GM, Fusco A.

J Clin Endocrinol Metab. 2012 May;97(5):E710-8. doi: 10.1210/jc.2011-3068. Epub 2012 Mar 7.


Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.

Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM.

Science. 2008 Dec 12;322(5908):1695-9. doi: 10.1126/science.1165395. Epub 2008 Nov 13.


Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer.

Zhang B, Liu XX, He JR, Zhou CX, Guo M, He M, Li MF, Chen GQ, Zhao Q.

Carcinogenesis. 2011 Jan;32(1):2-9. doi: 10.1093/carcin/bgq209. Epub 2010 Oct 15.


The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb group protein EZH2 in cancer.

Friedman JM, Jones PA, Liang G.

Cell Cycle. 2009 Aug;8(15):2313-4. Epub 2009 Aug 15. No abstract available.


Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression.

Bao B, Ali S, Banerjee S, Wang Z, Logna F, Azmi AS, Kong D, Ahmad A, Li Y, Padhye S, Sarkar FH.

Cancer Res. 2012 Jan 1;72(1):335-45. doi: 10.1158/0008-5472.CAN-11-2182. Epub 2011 Nov 22.


miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis.

Smits M, Nilsson J, Mir SE, van der Stoop PM, Hulleman E, Niers JM, de Witt Hamer PC, Marquez VE, Cloos J, Krichevsky AM, Noske DP, Tannous BA, Würdinger T.

Oncotarget. 2010 Dec;1(8):710-20.


Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.

Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S, Sarkar FH.

Cancer Prev Res (Phila). 2012 Mar;5(3):355-64. doi: 10.1158/1940-6207.CAPR-11-0299. Epub 2011 Nov 15.


MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.

Zhang JG, Guo JF, Liu DL, Liu Q, Wang JJ.

J Thorac Oncol. 2011 Apr;6(4):671-8. doi: 10.1097/JTO.0b013e318208eb35.


Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.

Au SL, Wong CC, Lee JM, Fan DN, Tsang FH, Ng IO, Wong CM.

Hepatology. 2012 Aug;56(2):622-31. doi: 10.1002/hep.25679. Epub 2012 Jun 11.


Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase.

Derfoul A, Juan AH, Difilippantonio MJ, Palanisamy N, Ried T, Sartorelli V.

Carcinogenesis. 2011 Nov;32(11):1607-14. doi: 10.1093/carcin/bgr184. Epub 2011 Aug 8.


Downregulation of microRNA-26a is associated with metastatic potential and the poor prognosis of osteosarcoma patients.

Song QC, Shi ZB, Zhang YT, Ji L, Wang KZ, Duan DP, Dang XQ.

Oncol Rep. 2014 Mar;31(3):1263-70. doi: 10.3892/or.2014.2989. Epub 2014 Jan 21.


The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2.

Friedman JM, Liang G, Liu CC, Wolff EM, Tsai YC, Ye W, Zhou X, Jones PA.

Cancer Res. 2009 Mar 15;69(6):2623-9. doi: 10.1158/0008-5472.CAN-08-3114. Epub 2009 Mar 3.


SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.

Coda DM, Lingua MF, Morena D, Foglizzo V, Bersani F, Ala U, Ponzetto C, Taulli R.

Cell Cycle. 2015;14(9):1389-402. doi: 10.1080/15384101.2015.1005993.


FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway.

Kottakis F, Polytarchou C, Foltopoulou P, Sanidas I, Kampranis SC, Tsichlis PN.

Mol Cell. 2011 Jul 22;43(2):285-98. doi: 10.1016/j.molcel.2011.06.020.

Items per page

Supplemental Content

Write to the Help Desk